MCAM and non-small cell lung carcinoma: Our results indicated that a high ratio of IL32 expression to pericyte marker expression, such as MCAM, PDGFRB, or ACTA2, was also linked to poor overall survival in NSCLC patients (Figure S1O, Supporting Information).